Pharmacy Grand Rounds

Banking Cost Savings with Biosimilars

• ACPE Universal Activity Number (UAN): JA0000238-0000-20-028-L01-P
• Session Type: Knowledge-based
• CE Credits: A maximum of 0.75 contact hour (0.075 CEU) for the following: 
  • AAPA Category 1 CME Credits
  • ACPE
  • AMA PRA Category 1 Credits™
  • ANCC

• Session Fee: Free for Mayo Clinic staff

SESSION LOCATIONS

Live Session: (11:00am - 11:45am CST)

Until future notice, learners must watch Pharmacy Grand Rounds live via the web by going to the Video Exchange and selecting “Pharmacy Grand Rounds” in the “Streaming Now” section.

Participants may attend by viewing: Live Webcast
Video Recording - access two weeks after session date

COURSE DESCRIPTION

Over the last decade, the Food and Drug Administration (FDA) has granted approval for several biosimilars to many medications that have historically made up a majority of drug spend for hospitals. Transitioning clinical practice to include these and replace more expensive reference products has generated some pause due to uncertain clinical implications and logistic concerns or other barriers. However, the potential for significant cost savings prompts more consideration into exploring implementation efforts, economic effects and patient outcomes.

At the conclusion of this knowledge-based CE session, participants should be able to:

1. Review pharmacoeconomic effects of biosimilar incorporation into clinical practice
2. Identify clinical areas where implementation of biosimilars may be most cost effective
3. Evaluate literature reviewing clinical outcomes for patients transitioned to biosimilar agents

Session Announcement

Session Slides

FACULTY INFORMATION

Dylan L. Kosaski, PharmD
PGY-1 Health System Pharmacy Administration Resident
Mayo Clinic Hospital - Rochester, MN

Dylan received a Doctor of Pharmacy degree from Ferris State University in Grand Rapids, MI. He is currently in the first year of a two year Health System Pharmacy Administration residency at Mayo Clinic – Rochester. As a part of his residency training he is also completing a Masters of Business Administration in Health Informatics through New England College. His practice interests in pharmacy operations management, cardiology, and psychiatry.

DISCLOSURE STATEMENTS

As a provider accredited by Joint Accreditation Interprofessional Continuing Education, Mayo Clinic College of Medicine and Science (Mayo Clinic School of CPD) must ensure balance, independence, objectivity and scientific rigor in its educational activities. Course Director(s), Planning Committee Members, Faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity. Safeguards against commercial bias have been put in place. Faculty also will disclose any off label and/or investigational use of pharmaceuticals or instruments discussed in their presentation. Disclosure of these relevant financial relationships will be published in activity materials so those participants in the activity may formulate their own judgments regarding the presentation.

Listed below are individuals with control of the content of this program:

The faculty report the following relationships:

• Dylan L. Kosaski, PharmD
  • Declares no financial relationships pertinent to this session
  • Declares off-label use of devices and medications will not be discussed during this presentation.

Course Director and Planning Committee Members declare no relevant financial relationship(s) pertinent to this session.  Members include:

• Brenda Amaris
• Mary Ellen Cordes, MS, APRN, CNC, NE-BC
• Michael Huckabee, MPAS, PA-C, PhD
• Wayne (Nick) Nicholson, MD, PharmD, BCPS
• Garrett Schramm, PharmD, BCPS
• Lee Skrupky, PharmD, BCPS